Brightling CE. Myeloid-derived suppressor cell-like fibrocytes are increased and associated with preserved lung function in chronic obstructive pulmonary disease. 
inflammation are central to the development of small airwaydependent air trapping, obliteration and emphysema (1, 3, 4) that are important contributors to airflow limitation (5) . In contrast to anti-inflammatory strategies that have harnessed our improved understanding of biological heterogeneity to improve patient management (6) , the cellular mechanisms involved in small airway remodelling are poorly understood and impede therapeutic development.
Fibrocytes are bone marrow-derived (7), CD45 + , CD34
+ cells that constitutively express ECM proteins (such as collagen type 1) (8) , circulate independently of monocytes (9) , utilize matrix metalloproteinase-8 (10) and chemokine receptors, such as CCR2 (11) , CCR3, CCR5 (12) and CXCR4 (13) , and migrate to sites of remodelled airway (14) . Once in tissue, fibrocytes downregulate CD34 expression (14) and contribute to immunopathological responses through paracrine actions on resident fibroblasts (15) rather than by direct collagen production (16) . Fibrocytes constitute <0.5% of human peripheral blood mononuclear cells (PBMCs) (8, 13) , circulate at a low concentration (≤5 9 10 4 cells/ml) (14, (17) (18) (19) (20) (21) and are traditionally isolated by ex vivo culture from a CD14 + precursor (17) , although recently CD14 À myeloid-derived suppressor cell (MDSC)-like fibrocytes have been identified in patients with cancer (22) . Fibrocytes have been reported to be an important biomarker of mortality in interstitial lung disease (23, 24) . Studies in asthma have shown that, compared to controls, blood fibrocytes are increased~10 times in those with chronic obstructive asthma (25, 26) , 3-4 times in allergen-exacerbated asthma (19) , atopic asthma (21) and in severe, but not mild, asthma (12, 20) . In the lungs of asthmatic subjects, fibrocytes have been detected in the lumen (21) , lamina propria (14, 20, 27) and smooth muscle of the large airway (20) . Moreover, in asthma, fibrocytes are associated with airway remodelling (27) and yearly decline in airflow limitation (FEV 1 ) (25) . In COPD, fibrocytes, identified by culture of PBMCs, appear to be increased during an exacerbation and decrease following resolution and are associated with early mortality (28) . It remains unclear whether fibrocytes are increased in the circulation (and in tissue) during stable periods of disease and whether fibrocyte levels are clinically important. Flow cytometry on ex vivo blood/PBMCs has been utilized previously to identify and enumerate fibrocytes (22) (23) (24) (29) (30) (31) (32) (33) (34) , but there is little consensus on how this should be achieved. We have applied a more rigorous flow cytometric protocol to determine whether constitutive collagen type 1 + cells present in PBMCs, in particular CD45 + , CD34
+ (classical) fibrocytes, are important to COPD immunopathology. Our hypothesis was that, compared to healthy controls, fibrocytes are increased in stable and exacerbation episodes of COPD and are related to lung function impairment.
Methods

Subjects
Subjects with COPD as per global initiative for obstructive lung disease (GOLD) criteria (35) that were participating in MRC/ABPI consortium COPD-MAP (n = 41) and control subjects (n = 29) with normal lung function were recruited to an observational study to identify blood fibrocytes. Further details are provided in the Supporting information. To identify tissue fibrocytes, macroscopically normal, lung resection material was ethically obtained from a separate cohort of patients with a lung cancer diagnosis under the auspices of the Midlands Lung Tissue Consortium and categorized into COPD and non-COPD (as a 'disease control') groups as per GOLD criteria (Table S1 ). All study visits took place at the University Hospitals of Leicester NHS Trust, Leicester, UK, and all subjects gave written informed consent to participate in a study approved by the Leicestershire, Northamptonshire and Rutland ethics committee (UHL10402, UHL10410 and UHL10613).
Quantitative computed tomography
Quantitative computed tomography (qCT) was performed and analysed by a single observer (RH), blinded to the study data, as described previously (5) and in the Supporting information. Air trapping on CT was quantified, per lobe, on expiratory scans using the mean lung density expiratory/inspiratory ratio (MLD E/I ), measured in Hounsfield units (HU) (5) . The HU that represents the lower 15% of voxels on a full inspiratory scan was used to calculate emphysema severity (Perc 15 ) and percentage airway wall area (WA%) was determined as an index of airway morphometry (5) (Table S2) .
Flow cytometry
Peripheral blood mononuclear cells were isolated from heparinized whole blood using Ficoll-Paque plus (GE Healthcare, Amersham, UK) and stained for 'classical' fibrocytes (defined in this study as CD45 + CD34 + collagen type 1 + ) in an Fluorescence minus one (FMO) set-up as described in the Supporting information. At least 300 000 CD45 + events were acquired on a CST calibrated BD FACSAria II and subjected to analysis using FLOWJO version 10 (Tree star, OR). Briefly, we removed unwanted artefacts (doublets, dead cells, contaminating neutrophils) from stained PBMCs (Fig. S1) tiplied by the total PBMC count (determined by haemocytometer) to give cells/ml of blood) of each population were reported. In addition, we measured the collagen content (DGMFI collagen type 1) of each fibrocyte population in a subset of control and COPD subjects (where we were able to record ≥200 collagen type 1 + events and all of which were stained with the same antibody lot number) to determine whether there were any phenotypic differences between fibrocytes from control and COPD subjects.
Immunohistochemistry
In a separate group of subjects, proximal and parenchymal lung tissue sections were embedded in glycol methacrylate resin and stained (brown labelling) for a-smooth muscle 15 and MLD E/I (further details in the Methods section of the Supporting information and in Table S3 ). A P-value ≤ 0.05 was taken as statistically significant.
Results
Quantification of blood fibrocytes and MDSC-like fibrocytes
The clinical characteristics and qCT parameters of the COPD subjects recruited for blood collection are shown in Tables 1  and S2 , respectively. The frequency (of total CD45 + cells) and concentration (cells/ml) of blood fibrocytes and MDSC-like fibrocytes in COPD subjects and controls are presented in Fig Fig. 2A,B ). The fibrocyte concentration was also increased in COPD [geometric mean (95% CI), 654 (383-1119) vs 1115 (726-1711) cells/ml of blood, respectively, P = 0.12], but this did not reach statistical significance (Fig. 2C ). In contrast, the geometric mean (95% CI) concentration of MDSClike fibrocytes ( Fig. 2D ) was significantly increased compared to control subjects [2481 (1390-4431) vs 5717 (3364-9713) cells/ml of blood], which represents a fold change (95% CI) of 2.3 (1.1-4.9), P = 0.038. There were no differences in fibrocyte or MDSC-like fibrocyte levels between study groups separated by smoking status by ANOVA (data not shown). There were significant differences in fibrocyte frequency, but not concentration, across study groups separated by gender (P = 0.044 ANOVA), and post hoc analysis showed a trend towards higher levels in males compared to females in the COPD group (P = 0.056), whereas all other comparisons had a P-value > 0.5. In contrast, there were no significant differences in MDSC-like fibrocyte frequency or concentration across study groups separated by gender (data not shown). Furthermore, the frequency and concentration of fibrocytes and MDSC-like fibrocytes were not correlated with age, pack-year history (Table S4) or GOLD status (data not shown). To determine whether the synthetic capacity of fibrocytes is higher in COPD, owing to cell extrinsic pro-fibrotic mediators such as TGF-b (17), we measured specific collagen type 1 fluorescein isothiocyanate expression (DGMFI), but these comparisons were not statistically significant (Fig. 2E,F) .
Fibrocytes are present in the COPD and non-COPD proximal airway
The clinical characteristics of subjects that donated lung resection material for fibrocyte detection are shown in Table S1 . Tissue fibrocytes, defined as CD34 + collagen type 1 + cells, were detected in nine of 22 proximal tissue specimens from COPD (4/11) and non-COPD (5/11) subjects (Fig. 3A,B) but not in small airway tissue specimens derived from five COPD subjects (data not shown). In contrast to subjects with severe asthma (20) , tissue fibrocytes were not located within the airway smooth muscle bundle of the proximal airway but were present in the subepithelial region of the proximal airway (Fig. 3A,B ) and occasionally adjacent to airway smooth muscle. There was no difference in the number of proximal airway fibrocytes/mm 2 between COPD and non-COPD controls [median (IQR) non-COPD 0 (0-2) vs COPD 0 (0-1.3), P = 0.69, n = 11 in each group]. Tissue and blood fibrocytes are associated with eosinophilic COPD
We detected a significant relationship between the number of tissue fibrocytes/mm 2 and tissue (mm 2 ) eosinophils for COPD (r = 0.67, P = 0.03) and non-COPD (r = 0.72, P = 0.017) subjects (Fig. 3C , showing COPD and non-COPD groups combined) but not thickness of the reticular basement membrane (Spearman r = 0.036) or spirometry (data not shown). Chronic obstructive pulmonary disease patients categorized into lower (<0.2 9 10 9 /l) vs higher (≥0.2 9 10 9 /l) blood eosinophils also had differential levels of tissue fibrocytes (Fig. S3A) .
The relationship between blood fibrocytes and eosinophils was also present in blood (Fig. 3D) . We detected a significant association between blood fibrocytes and blood eosinophil 3D and S3B and Table S4 ), and eosinophil frequency (Table S4 ) and blood monocytes (Fig. S3C ) in COPD subjects. In contrast, there was no significant relationship between COPD blood fibrocytes and sputum eosinophils and blood/sputum neutrophils (Table S4) .
Relationship between blood fibrocytes and COPD severity
We next examined the relationship between blood fibrocytes, questionnaire symptoms and health status (Table S4) where we found a significant negative association with the CRQ dyspnoea domain (Table S4 and Fig. S3D ) but not modified medical research council (mMRC) breathlessness (data not shown) nor VAS dyspnoea (Table S4) score was not (data not shown). The frequency and concentration of fibrocytes, however, were not independently associated with the frequent exacerbation phenotype in a logistic regression analysis (data not shown) and furthermore we could not detect an increase in fibrocyte levels at exacerbation visits (n = 11) compared to stable visits (n = 41) in a cross-sectional [geometric mean (95% CI) stable 0.08 (0.06-0.12) vs exacerbation 0.08 (0.05-0.14)] or paired analysis (data not shown, n = 7). Importantly, given the putative role of fibrocytes, fibrocyte %, fibrocyte concentration and collagen content were not related with lung function (measured by spirometry), GOLD stage, airway morphometry or densitometry (qCT data) (Tables S4 and S5 ).
The MDSC-like fibrocyte phenotype is associated with improved airflow limitation through a small airway rather than emphysema-dependent mechanism
The frequency and concentration of MDSC-like fibrocytes were not consistently associated with any biological or clinical parameter (Table S4 ). The immunoreactivity of MDSClike fibrocytes with the collagen antibody (specific collagen type 1, DGMFI), however, was significantly associated with less air trapping (total MLD E/I r = À0.38, P = 0.05, n = 27), but not postbronchodilator % predicted FEV 1 , postbronchodilator FEV 1 /FVC nor Perc 15 ( Figs 4A,B and S4A,  B) . Interestingly, the relationship between MLD E/I and MDSC-like fibrocyte collagen DGMFI was observed to have a regional distribution with significant associations with the upper lobes (left upper r = À0.45, P = 0.02, and right upper r = À0.47, P = 0.01, Fig. 4C,D) , which were not observed in the middle or lower lobes (Fig. S4C,D and Table S5) . MLD E/I (total) and Perc 15 were both associated with % predicted FEV 1 (r = À0.81, P = 0.0001 and r = 0.53, P = 0.0016, respectively). Thus, to determine any potential contribution of the MDSC-like fibrocyte phenotype upon airflow limitation either directly or possibly via air trapping or emphysema, we constructed a path analysis model (Fig. 4E) . The path analysis model showed that the MDSC-like fibrocyte phenotype did not have a significant association with airflow limitation directly or through emphysema but was associated with airflow limitation through MLD E/I (Fig. 4E and Table S6 ). This relationship was still significant when we omitted subjects with missing data (n = 27) ( Table S7 ).
Discussion
Our aims were to measure blood and tissue collagen type 1 + cells and determine whether they are associated with clinical features of disease. Our main findings were that we identified two collagen type 1 + cell populations in blood: (i) CD34 + fibrocytes associated with eosinophilic COPD but not lung physiology measured by spirometry or qCT and (ii) CD34 À MDSC-like fibrocytes, increased 2.3-fold in COPD subjects, whose fibrocyte-like phenotypes were associated with less (upper lobe) small airway-dependent, airflow limitation in COPD. A strength of this study was that we applied our flow cytometric protocol to measure blood fibrocytes directly on freshly isolated PBMCs from a large group of well-characterized, stable COPD patients. In doing so, we removed confounding variables such as putting cells through a freeze/thaw cycle (23), culture (28) and granulocytes (37) from our analysis. Moreover, we also included a viability dye, an FMO set-up (but, where appropriate, included isotype controls), CD34 expression as an obligatory 'classical' fibrocyte marker and ensured that our gated populations had homogenous light scatter properties (38) , to increase the stringency of our analysis. Technical differences such as these may account for the (at least) 10-fold lower frequency and concentration of fibrocytes in our study, compared to other investigators (28, 37) . In this study, we have identified ('classical') fibrocytes as CD45 + collagen type 1 + CD34 + cells (8, 14, 17) that also expressed CD14, consistent with others (12) and in agreement with the observation that fibrocytes develop ex vivo from a CD14 + precursor (17) . Importantly, we were also able to show that CD14 + monocytes were collagen type 1 À in these samples (Figs S1F and S2).
A principle finding from our study was that fibrocytes remain very low in stable (noneosinophilic) COPD and, importantly given their putative role in asthma, are not associated with lung function severity or qCT data. Dupin et al. (28) recently showed that stable (nonexacerbating) COPD patients have fibrocyte levels similar to control subjects and thus our studies appear similar; however, we were unable to find evidence to support an association between fibrocytes and lung function. Furthermore, we were not able to support findings made by Dupin et al. that fibrocytes are increased at presentation of an exacerbation although we were in agreement in showing that fibrocytes are significantly increased in COPD patients with a history of frequent exacerbations; however, this observation was no longer significant following multiple regression analysis.
We did find a striking and novel positive association between fibrocytes and eosinophil levels in both COPD blood and tissue compartments but not sputum, although in the latter there was a trend towards significance (Table S4 ). This discrepancy may be attributed to the lower number of sputum eosinophil measurements obtained (n = 33) compared with blood eosinophil measurements (n = 41). Ten to 20% of COPD patients have increased levels of eosinophils (2), benefitting from T2-directed management (6), and our blood and tissue data suggest that fibrocytes may be more important within this subgroup. Differences in blood and tissue fibrocyte levels between our COPD patients and fibrocyte levels in asthma (25) may be related to the higher proportion of subjects with a more classical pattern of T2 inflammation in asthma (39) . T2 chemokines (12) and cytokines (21, 40) have been shown to augment tissue trafficking, differentiation and pro-fibrotic activity of fibrocytes. Eosinophil and fibrocyte responses are thus likely to be coordinated and warrant further study in the context of anti-T2 therapies, such as anti-IL-5, which has been shown to reduce basement membrane thickness in mild asthma (41) .
We also examined proximal and small airway COPD tissue for the presence of fibrocytes, which is a novel aspect of this study. Our study aim was to determine whether blood fibrocytes were important in COPD without a specific emphasis, a priori, on their contribution towards the development of subepithelial fibrosis, which may be indirect (16) . Our tissue fibrocyte data complemented our blood fibrocyte observations and suggest that at least in moderate COPD (without elevated eosinophils), fibrocytes may not be an important contributor to proximal and small airway immunopathology, although we cannot rule out their involvement in the tissue of subjects with more severe COPD, which we did not examine. A limitation of our approach is that our macroscopically normal lung tissue was obtained from patients with a diagnosis of lung cancer (Table S1 ), which may have had an impact on fibrocyte levels. However, our tissue fibrocyte levels (in both control and COPD groups) per mm 2 of lamina propria were very similar to data, shown previously from our group, derived from bronchial biopsy specimens collected from healthy volunteers without cancer (20) . This suggests that the cancer diagnosis is likely to have had little effect on the data we generated from macroscopically normal tissue and as fibrocytes were low across all groups we felt we could not justify further invasive samples to be collected from healthy subjects.
A further novel approach that we undertook was to analyse CD45 + collagen type 1 + cells, with differential (but homogenous) light scatter properties, separately, without relying on expression of, promiscuously expressed, chemokine receptors (37, 38) . We thus identified a population of CD45 Fig. 1 ). Although they are HLA-DR À , we did not confirm the immunosuppressive nature of these cells and we chose to use the term MDSC-like cells throughout this manuscript. This is the first time, however, that MDSCs with a fibrocyte-like phenotype have been reported to be increased (2.3-fold) in COPD. A further limitation of our study was that there were some demographic differences, such as age, gender and smoking history, between our control and COPD subjects. Importantly, we did not find an association between the frequency or concentration of MDSC-like fibrocytes and age, gender, pack-year history or disease severity (GOLD).
Moreover, we were able to show that current smokers in the COPD group were not driving this increase in MDSC-like fibrocytes.
We were subsequently able to show that the phenotypic shift towards an MDSC-like fibrocyte phenotype may be clinically relevant through an association with less severe air trapping and ultimately lung function using path analysis. Importantly, we have recently shown that air trapping (MLD E/I ) is an important contributor to lung function impairment in COPD and asthma (5) . A strength of this study is that we examined regional as well as total MLD E/I , which allowed us to detect novel regional associations that would have otherwise been masked by total lung MLD E/I data. Interestingly, our observations were strongest in both upper (Fig. 4C,D) , but not lower, lobes of the lung (Fig. S4C,D) , which is a more dominant location of small airway disease (1) and centrilobular emphysema (4) in COPD. In contrast, the frequency and concentration of MDSC-like fibrocytes were not related to qCT data. These data suggest that the drivers of the MDSC-like collagen type 1 + phenotype may have more important modifying effect on COPD disease severity than frequency or concentration of the cells themselves. A limitation of our analysis is that our observations were modest and we have not investigated the likely mechanism(s). Myeloid-derived suppressor cell-like fibrocytes have been shown to differentiate (under the influence of IL-4) from a collagen type 1
+ precursor into a collagen type 1 + , CD14 À population, which can inhibit Tcell proliferation utilizing indolamine (22) . We speculate that the anti-inflammatory properties of MDSC-like fibrocytes may, in part, contribute towards the association with improved lung function by limiting small airway, T-celldependent inflammation, although this (and the role of T2 cytokines) requires further study.
In conclusion, our data show that fibrocytes are biologically important in eosinophilic COPD and thus warrant further investigation as contributors to airway remodelling (including fibrosis) in this COPD group. In contrast, blood MDSC-like fibrocytes are increased in COPD and may have a beneficial role by limiting small airway-dependent lung function impairment.
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